Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from QuantumPharm, Inc. ( (HK:2228) ) is now available.
XtalPi Holdings Limited has entered into a term sheet with DoveTree LLC to collaborate on drug discovery using its AI and robotics platform. This partnership will focus on developing small molecule and antibody drug candidates for tumors, autoimmune, and neurological diseases, potentially leading to significant financial gains and global commercialization rights for DoveTree.
The most recent analyst rating on (HK:2228) stock is a Buy with a HK$7.57 price target. To see the full list of analyst forecasts on QuantumPharm, Inc. stock, see the HK:2228 Stock Forecast page.
More about QuantumPharm, Inc.
XtalPi Holdings Limited is a company that focuses on providing drug discovery and material science R&D solutions through integrated ‘AI + robotics’ technology. The company aims to enhance its intelligent autonomous experimental platform to bring breakthrough therapies to patients globally.
Average Trading Volume: 92,401,777
Technical Sentiment Signal: Buy
See more insights into 2228 stock on TipRanks’ Stock Analysis page.